✦ LIBER ✦

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

✍ Scribed by K. Berger; T. Fischer; T.D. Szucs

Book ID: 117665963
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 81 KB
Volume: 34
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(98)00260-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

OP2. Cost-effectiveness analysis of pacl

OP2. Cost-effectiveness analysis of paclitaxel and cisplatinum versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer — A European perspective

✍ K Berger; T Szucs 📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 174 KB

Is paclitaxel and cisplatin a cost-effec

Is paclitaxel and cisplatin a cost-effective first-line therapy for advanced ovarian carcinoma?

✍ Allan Covens; Sylvain Boucher; Kathie Roche; Moira Macdonald; Daniel Pettitt; Br 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 567 KB

## BACKGROUND. Paclitaxel and cisplatin use for the treatment of advanced ovarian carcinoma (AOC) has been shown to increase median sunrival duration. An evaluation was performed on the economic consequences of treating AOC patients with combined paclitaxel and cisplatin chemotherapy compared with

Carboplatin and Paclitaxel versus Cispla

Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study

✍ Gerasimos Aravantinos; George Fountzilas; Aristotelis Bamias; Irene Grimani; Spy 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 191 KB

CH1: COST-EFFECTIVENESS ANALYSIS OF IRIN

CH1: COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER

✍ C Schmitt; C Levy-Piedbois; M Frappe; I Durand-Zaleski 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

A Phase I/II Study of Dose-Intense Pacli

A Phase I/II Study of Dose-Intense Paclitaxel with Cisplatin and Cyclophosphamide as Initial Therapy of Poor-Prognosis Advanced-Stage Epithelial Ovarian Cancer

✍ Elise C. Kohn; Gisele A. Sarosy; Patricia Davis; Michaele Christian; Charles E. 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 154 KB

Pharmacoeconomic profile of paclitaxel a

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis

✍ Andrea Messori; Michele Cecchi; Paola Becagli; Sabrina Trippoli 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL. predisposes patients to the deve